RARE NASDAQ
Ultragenyx Pharmaceutical Inc.
1W: +5.0%
1M: -42.6%
3M: -54.8%
YTD: -35.5%
1Y: -49.2%
3Y: -58.8%
5Y: -84.0%
$15.22
+0.47 (+3.19%)
Weekly Expected Move ±9.7%
$12
$14
$15
$17
$18
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships5
As Filer
counterparties named
1
As Counterparty
mentioned by others
3
Rel. Types
2021-05-07
Earliest Filing
2025-11-04
Latest Filing
investor: 2
partner: 2
target: 1
Counterparties (Filed by RARE)
5 relationshipsCompanies named in RARE's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| OCM LS23 Holdings LP | — | investor | Investment vehicle of OMERS that purchased a 25% royalty interest in Crysvita sales from Ultragenyx for $400 million. | 2025-11-04 | View |
| OMERS | — | investor | Investment firm through its vehicle OCM LS23 Holdings LP that acquired a portion of Ultragenyx's Crysvita royalty rights | 2025-11-04 | View |
| Kyowa Kirin Co., Ltd. | — | partner | Partner with Ultragenyx under a Collaboration and License Agreement for the commercialization of Crysvita in the US and | 2025-11-04 | View |
| GeneTx Biotherapeutics LLC | — | target | Acquired by Ultragenyx Pharmaceutical Inc. for $75 million upfront plus milestones and royalties. | 2022-07-18 | View |
| Jefferies LLC | JEF | partner | Agent for Open Market Sale Agreement | 2021-05-07 | View |
Mentioned As Counterparty
1 mentionsOther companies that named RARE in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-17 | Other Events | View | |
| 2026-09-02 | Other Events | View | |
| 2026-08-19 | Other Events | View | |
| 2026-08-11 | Other Events | View | |
| 2026-08-04 | Earnings Release; Exhibits | View | |
| 2026-05-18 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-05 | Earnings Release; Exhibits | View | |
| 2026-04-02 | Other Events | View | |
| 2026-03-30 | Other Events | View | |
| 2026-03-12 | Other Events | View | |
| 2026-02-23 | Other Events | View | |
| 2026-02-12 | Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities; Fi | View | |
| 2026-02-03 | Other Events | View | |
| 2026-01-30 | Other Events | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-30 | Other Events | View | |
| 2025-12-29 | Other Events | View | |
| 2025-11-04 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Financial S | Agreement | View |
| 2025-10-30 | Other Events | View | |
| 2025-09-08 | Other Events | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR